Bionik Laboratories Corp. (OTCMKTS:BNKL) Files An 8-K Entry into a Material Definitive Agreement
On February 13, 2019, Bionik Laboratories Corp. (the “Company”) entered into (a) an Allonge to Convertible Promissory Notes (the “2018-2019 Note Allonge”), with respect to those certain convertible promissory notes issued by the Company between September 2018 and January 2019 in the aggregate principal amount of $4,650,000 (the “2018-2019 Notes”) and (b) an Allonge to Convertible Promissory Notes (the “Short Term Note Allonge” and, with the 2018-2019 Note Allonge, the “Allonges”), with respect to those certain short-term convertible promissory notes issued by the Company between June 2018 and July 2018 in the aggregate principal amount of $4,708,306 (the “Short-Term Notes”).
to the 2018-2019 Note Allonge, the 2018-2019 Notes were amended to reflect that the securities issued to the holders thereof upon conversion of the 2018-2019 Notes upon the consummation of a Qualified Financing (as defined in the 2018-2019 Notes) be the same securities as issued in the Qualified Financing.
to the Short Term Note Allonge, the Short Term Notes were amended to reflect that the securities issued to the holders thereof upon any triggering of the anti-dilution clause found in Section 3.4 of the Short Term Notes be the same securities as issued in the Offering (as defined in the Allonge).
The foregoing description of the Allonges is not complete and is subject to and qualified in its entirety by reference to the Allonges, forms of which are attached as Exhibits 10.1 and 10.2 to this Current Report on Form 8-K, and are incorporated herein by reference.
|Item 9.01||Financial Statements and Exhibits.|
Bionik Laboratories Corp. Exhibit
EX-10.1 2 tv513640_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 ALLONGE TO CONVERTIBLE PROMISSORY NOTES Allonge (this “Allonge”) to those certain Convertible Promissory Notes (the “Convertible Notes”) referenced hereto in Exhibit 1 and made a part hereof,…
To view the full exhibit click
About Bionik Laboratories Corp. (OTCMKTS:BNKL)
Bionik Laboratories Corp. (Bionik), formerly Drywave Technologies, Inc., is a medical device and robotics company. The Company is focused on providing rehabilitation solutions and developing transformational technologies and solutions to individuals with neurological disorders, specializing in the designing, developing and commercializing of physical rehabilitation technologies, prosthetics and assisted robotic products. It has over three products on the market and approximately three products in various stages of development. The InMotion Systems include the InMotion ARM, InMotion HAND, InMotion Wrist and InMotion ANKLE are designed to provide patent-adaptive therapy in a manner that has been clinically verified to manage neuro-recovery. The Company is also engaged in developing a lower-body exoskeleton, ARKE, which designs to allow paraplegics, as well as other wheelchair users the ability to rehabilitate through walking.